Open AccessCombination of ceftaroline and daptomycin as treatment for complicated osteomyelitis
Author(s) -
Ana Gascón,
Marta Castresana,
Natalia Alzueta,
Marta Marin,
María Pío,
Alberto Echeverría
Publication year - 2020
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2019-002183
Subject(s) - daptomycin , osteomyelitis , medicine , staphylococcus epidermidis , teicoplanin , antimicrobial stewardship , vancomycin , antibiotics , staphylococcus aureus , antimicrobial , microbiology and biotechnology , intensive care medicine , antibiotic resistance , surgery , biology , bacteria , genetics
Osteomyelitis is an infection involving bone. Staphylococcus aureus is the pathogen most frequently implicated; less frequently involved are other gram-positive organisms, such as Staphylococcus epidermidis, and also gram-negative organisms. The antibiotic of choice for treatment of osteomyelitis caused by methicillin-resistant staphylococci (MRS) is vancomycin, although other alternatives such as daptomycin or teicoplanin are also considered. Osteomyelitis caused by MRS can be difficult to treat safely and effectively. This case report describes the successful use of daptomycin combined with ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant S. epidermidis (MRSE) in a 54-year-old woman, emphasising the clinical pharmacist's role in antimicrobial stewardship programmes. This alternative combination has been studied in the treatment of methicillin-resistant S. aureus (MRSA), but it may also be useful in MRSE.